Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigating Radiation-response and Toxicity
M.D. Anderson Cancer Center · NCT06909201
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · All sexes
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 70
- US sites recruiting
- 1
- Study start
- March 31, 2026
- Record last updated
- August 25, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The goal of this clinical research study is to learn if novel type of imaging scan called HP 129Xe MRI can help doctors identify and predict common side effects of radiation therapy. Rather than contrast-enhanced MRIs, the tracer (129Xe) will be inhaled rather than injected.
The 129Xe tracer has not been FDA approved. Its use in this study is investigational.
Being studied: HP 129Xe MRI
Conditions: Lung Cancer
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Healthy control cohort:
- Able to consistently hold breath for 10-12 seconds
- No history of any pulmonary disorders (i.e., asthma, COPD, lung cancer, etc.)
- Able to undergo MRI examination
- At least 18 years of age
- Lung cancer patient cohort:
- Biopsy proven diagnosis of lung cancer
- Receiving photon- or proton-based external beam radiotherapy as a part of treatment
- Able to undergo MRI examination
- Will receive follow-up at University of Texas MD Anderson Cancer Center (UTMDACC)
- Able to consistently hold breath for 10-12 seconds
- Women and men with child-bearing potential agree to use adequate contraception prior to study entry and during the duration of study participation.
- Able to understand and willing to sign a written informed consent document
- At least 18 years of age
The effects of HP 129Xe MRI on the developing human fetus are unknown. For this reason and because radiotherapy is known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. (Refer to Pregnancy Assessment Policy MD Anderson Institutional Policy # CLN1114). This includes all female patients, between the onset of menses (as early as 8 years of age) and 55 years unless the patient presents with an applicable exclusionary factor which may be one of the following:
- Postmenopausal (no menses in greater than or equal to 12 consecutive months).
- History of hysterectomy or bilateral salpingo-oophorectomy.
- Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy).
- History of bilateral tubal ligation or another surgical sterilization procedure.
- Approved methods of birth control are as follows: Hormonal contraception (i.e. birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject/Partner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Additionally, if female partners of male study participants become pregnant during study participation, the treating physician should be informed immediately.
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria
- Patients unable to follow up at MD Anderson for routine clinical care
- Inability or unwillingness to give informed consent
- Relapsed disease or life expectancy less than 6 months at time of enrollment
- Severe claustrophobia precluding MRI imaging active pulmonary infection
- Pregnant women
- Under 18 years of age
Recruiting US locations
The University of Texas M. D. Anderson Cancer Center
Houston, TX 77030
Site contact: Joshua Niedzielski, PHD · 713-745-8946 · jsniedzielski@mdanderson.org
Study contacts (from the official record)
- Joshua Niedzielski, PHD · (713) 745-8946 · jsniedzielski@mdanderson.org
Similar studies in Texas
All healthy volunteers studies in Texas →- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Study of LY4355756 in Healthy Participants
Eli Lilly and Company
- Location
- Dallas, TX
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment
AstraZeneca
- Location
- San Antonio, TX + 1 other US site
- Eligibility basics
- Ages 18–80
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight
Eli Lilly and Company
- Location
- San Antonio, TX
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
Radiprodil in Participants With Hepatic Impairment
GRIN Therapeutics, Inc.
- Location
- DeSoto, TX + 1 other US site
- Eligibility basics
- Ages 18–75